Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes
Authors
Keywords
SGLT2, Type 2 diabetes, Diabetic nephropathy, AMPK, Inflammasome
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 32, Issue 2, Pages 135-145
Publisher
Springer Nature
Online
2018-03-05
DOI
10.1007/s10557-018-6778-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
- (2017) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- High glucose stimulates cell proliferation and Collagen IV production in rat mesangial cells through inhibiting AMPK-KATP signaling
- (2017) Bei Zhang et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Dipeptidyl peptidase-4 inhibitor sitagliptin prevents high glucose-induced apoptosis via activation of AMP-activated protein kinase in endothelial cells
- (2017) Chao Wu et al. Molecular Medicine Reports
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation
- (2017) Shaofei Wang et al. Cell Death & Disease
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals
- (2016) Yuji Ishibashi et al. Diabetes & Vascular Disease Research
- Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
- (2016) Ofri Mosenzon et al. DIABETES CARE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition
- (2015) Sen Shi et al. KIDNEY INTERNATIONAL
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
- (2014) Atsuo Tahara et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner
- (2013) Hans-Joachim Anders et al. KIDNEY INTERNATIONAL
- Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats
- (2012) Qing-Hua Hu et al. BIOCHEMICAL PHARMACOLOGY
- Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?
- (2012) Vishwa Deep Dixit DIABETES
- Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
- (2012) Hye-Mi Lee et al. DIABETES
- The Inflammasomes in Kidney Disease
- (2011) H.-J. Anders et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- NLRP3 inflammasomes link inflammation and metabolic disease
- (2011) Dominic De Nardo et al. TRENDS IN IMMUNOLOGY
- BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy
- (2010) K. L. Hudkins et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
- (2010) Seth L Masters et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started